Edition:
United Kingdom

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

54.87USD
7:00pm BST
Change (% chg)

$-0.36 (-0.65%)
Prev Close
$55.23
Open
$55.19
Day's High
$55.19
Day's Low
$54.84
Volume
3,001
Avg. Vol
54,530
52-wk High
$55.27
52-wk Low
$17.75

Latest Key Developments (Source: Significant Developments)

Reg-Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx
Wednesday, 28 Feb 2018 

March 1 (Reuters) - Sanofi ::* Sanofi has received clearance from the Federal Cartel Office of Germany in accordance with the Act Against Restraints of Competition, applicable to Sanofi's proposed acquisition of Ablynx NV .  Full Article

Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - ABLYNX NV ::FY OPERATING LOSS OF EUR 54.2‍​ MILLION VERSUS LOSS OF EUR 28.6 MILLION YEAR AGO.FY NET LOSS OF EUR 108.5‍​ MILLION VERSUS LOSS OF EUR 1.1 MILLION YEAR AGO.CASH POSITION AT DEC 31 EUR 354.3‍​ MILLION VERSUS EUR 235.4 MILLION YEAR AGO.FY TOTAL REVENUE AND GRANT INCOME EUR ‍​55.5 MILLION VERSUS EUR 85.2 MILLION YEAR AGO.MAY RECEIVE MARKETING AUTHORISATION FOR CAPLACIZUMAB IN ATTP IN Q3 2018.FOR ALX-0171, A PHASE II STUDY TO BE INITIATED IN H1 2018.RESULTS FROM ONGOING ALX-0171 PHASE IIB STUDY IN RSV-INFECTED HOSPITALISED INFANTS ARE EXPECTED IN Q4 2018.PHASE II RESULTS FOR VOBARILIZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS EXPECTED IN H1 2018.EXPECTS UP TO THREE NANOBODIES TO ENTER PHASE I STUDIES FROM OUR COLLABORATIVE PROGRAMMES DURING 2018.  Full Article

Sanofi CFO Refuses To Provide 2018 Outlook Excluding Recent Acquisitions Of Bioverativ, Ablynx
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Sanofi ::CFO REFUSES TO PROVIDE 2018 OUTLOOK EXCLUDING RECENT ACQUISITIONS OF BIOVERATIV, ABLYNX.CEO SAYS GROUP REMAINS “VERY COMMITTED” TO DENGVAXIA PROGRAM.CEO SAYS HAS REDUCED DIABETES AND CARDIOVASCULAR SALES STAFF BY 400 LAST YEAR IN THE U.S.CEO SAYS GROUP PLANS NO RESTRUCTURING MEASURES IN THE U.S THIS YEAR.  Full Article

Sanofi CFO sees cost of debt to finance Ablynx acquisition around 1 pct
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Sanofi Chief Financial Officer Jerome Contamine says::expects cost of debt to finance Ablynx acquisition to be around 1 percent.  Full Article

Ablynx Chairman, Peter Fellner, Resigns With Immediate Effect​
Monday, 8 Jan 2018 

Jan 8 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES BOARD CHANGES‍.DR PETER FELLNER DECIDED TO RESIGN FROM BOARD WITH IMMEDIATE EFFECT​.‍HE WILL BE SUCCEEDED BY DR BO JESPER HANSEN​.  Full Article

Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company
Monday, 8 Jan 2018 

Jan 8 (Reuters) - ABLYNX NV ::BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION.TODAY CONFIRMED THAT ON DEC 22, 2017 IT RECEIVED UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK A/S.J.P. MORGAN IS SERVING AS FINANCIAL ADVISOR TO ABLYNX.ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS.CO LONG-TERM STRATEGIC PLAN OF BECOMING FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY."BOARD SEES NO MERIT IN CEDING CONTROL OF ITS ASSETS WITHOUT FULL UPFRONT VALUE RECOGNITION FOR SHAREHOLDERS" - CEO.  Full Article

Novo Nordisk CFO Says Not Our Understanding That Any Other Bidder Is Pursuing Ablynx
Monday, 8 Jan 2018 

Jan 8 (Reuters) - NOVO NORDISK NOVOB.CO CHIEF FINANCIAL OFFICER JESPER BRANDGAARD SAID ON A CONFERENCE CALL IN RELATION TO BID FOR ABLYNX ::"IN TERMS OF COUNTER PROPOSALS IT IS NOT OUR UNDERSTANDING THAT ANY OTHER BIDDER IS PURSUING THE TARGET" nFWN1P3016.  Full Article

Novo Nordisk has proposed to buy Ablynx for up to 30.50 euros per share in cash
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Novo Nordisk ::HAS PROPOSED TO BUY ABLYNX FOR UP TO EUR 30.50 PER SHARE IN CASH, CONSISTING OF EUR 28.00 UPFRONT AND EUR 2.50 IN CONTINGENT VALUE RIGHTS​.‍PROPOSAL IMPLIES A TOTAL EQUITY VALUATION OF APPROXIMATELY EUR 2.6 BILLION FOR ABLYNX​.PROPOSAL IS SECOND PROPOSAL THAT CO HAS MADE TO ABLYNX'S BOARD AND REPRESENTS UP TO APPROXIMATELY A 14% INCREASE OVER FIRST PROPOSAL​.CO "REGRETS" THAT BOARD OF ABLYNX HAS SO FAR DECLINED TO ENGAGE IN ANY DISCUSSIONS, DESPITE PROPOSALS WHICH HAVE BEEN PUT FORWARD​.PROPOSAL ALSO CONSISTS OF ONE CONTINGENT VALUE RIGHT WITH TOTAL POTENTIAL CASH PAYMENTS OVER TIME OF UP TO EUR 2.50 PER SHARE​.  Full Article

Ablynx 9-month revenues decrease to 44.7 million euros ​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - ABLYNX NV : :9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​.9 MONTH ‍OPERATING LOSS OF EUR 42.1 MILLION (2016: EUR 13.6 MILLION)​.‍9 MONTH NET CASH BURN OF EUR 26.9 MILLION (2016: EUR 44.1 MILLION)​.9 MONTH ‍CASH POSITION OF EUR 208.6 MILLION (2016: EUR 263.6 MILLION)​.‍9 MONTH ENDED WITH NET LOSS OF EUR 45.8 MILLION (2016: NET PROFIT OF EUR 10.9 MILLION)​.  Full Article

Ablynx announces full exercise of underwriters' option to purchase additional shares
Friday, 27 Oct 2017 

Oct 27 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD.‍GREENSHOE OPTION GRANTED TO UNDERWRITERS FOR PURCHASE OF UP TO AN ADDITIONAL 1,714,500 NEW ORDINARY SHARES​.‍GREENSHOE EXERCISE BRINGS TOTAL GROSS PROCEEDS FOR OFFERING TO APPROXIMATELY $230 MILLION (EUR 195 MILLION)​.  Full Article

UPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 bln

* Healthcare sector has seen lots of M&A so far in 2018 (Adds detail)